Eosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient

Eosinophilic myocarditis (EM) is a rare cause of heart failure, with high in-hospital mortality associated with fulminant disease. A 61-year-old female transplant recipient was diagnosed with COVID-19 after presenting with 2 days of constitutional symptoms. She developed acute heart failure from EM. After an initial response to inotropic support and corticosteroids, she had a relapse with de novo peripheral eosinophilia which responded to further eosinophilic myocarditis management and the addition of mepolizumab. Although there have been reports after COVID-19 vaccination, association with active SARS-CoV-2 infection is rare. This paper reports, for the first time, the case of a heart transplant recipient with EM after COVID-19.

Authors

Institutions

Publication Details

Journal
JACC Case Reports
Published
2024-09-01
DOI
https://doi.org/10.1016/j.jaccas.2024.102527
Primary Topic
Eosinophilic Disorders and Syndromes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Eosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient

Jacob Colin Jentzer, Adrian daSilva‐deAbreu, Nandan S. Anavekar, Atta Behfar et al.
JACC Case Reports
Eosinophilic Disorders and Syndromes
article

Eosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient

Jacob Colin Jentzer, Adrian daSilva‐deAbreu, Nandan S. Anavekar, Atta Behfar, Leslie T. Cooper, Sara S. Inglis, Shannon M. Dunlay, Francisco B. Alexandrino, Anshul Gupta, Marie Christine Aubry
article en

Abstract

Eosinophilic myocarditis (EM) is a rare cause of heart failure, with high in-hospital mortality associated with fulminant disease. A 61-year-old female transplant recipient was diagnosed with COVID-19 after presenting with 2 days of constitutional symptoms. She developed acute heart failure from EM. After an initial response to inotropic support and corticosteroids, she had a relapse with de novo peripheral eosinophilia which responded to further eosinophilic myocarditis management and the addition of mepolizumab. Although there have been reports after COVID-19 vaccination, association with active SARS-CoV-2 infection is rare. This paper reports, for the first time, the case of a heart transplant recipient with EM after COVID-19.

JACC Case ReportsVol. 29(18)
Mayo Clinic (US), Jacksonville College (US), Mayo Clinic in Florida (US)
Good health and well-being
Openalex Percentile: Top 72%
Eosinophilic Disorders and Syndromes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Eosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient — Jacob Colin Jentzer, Adrian daSilva‐deAbreu, et al. · JACC Case Reports (2024) | TGRS Research Map | TGRS